NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BostonGene

BostonGene

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://bostongene.com/

Last Round

Series B

Apr 6, 2022

Est. Valuation

$2B

Total Funding Raised

$200M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BostonGene is a biotechnology company that develops an AI-powered, omnimodal analysis platform that integrates genomic, transcriptomic, immune, and clinical data to provide actionable insights for oncology drug development and personalized patient care.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics, Medical AI, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Foundation

Keywords

precision oncologyimmuno-oncologybiomarker discoverymulti-omicsAI foundation modelclinical trial matchingdigital twintumor profilingdrug response predictiondigital pathologyAI drug discoverycomputational biologybiotech AIoncology informaticstranslational medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BostonGene Comparables

Compare BostonGene with similar companies based on industry and business-model similarity.

BostonGene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tempus
83%
Caris Life Sciences
80%
ConcertAI
76%

BostonGene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 6, 2022
Series AApr 24, 2019

Key People

Founding team and executive leadership

Andrew Feinberg

President & CEO, Cofounder And Investor

Founding Team

Alexander Bagaev

Chief Product Officer

Executive Team

BostonGene Investors

Notable investors and investment history

BostonGene investors
InvestorRounds
Japan Industrial PartnersSeries B
Impact Investment ExchangeSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Launched an AI foundation model for tumor and immune biology.

  • May 17, 2026

    Launched Liquid BiopsyTM clinical report.

BostonGene Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BostonGene Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BostonGene's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range370
Year Founded2015
Last FundingApr 6, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.